[
    {
        "id": 2396,
        "drug_name": "GILENYA (Fingolimod)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple Sclerosis (MS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-11",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-fda-approval-gilenyar-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis",
        "note": "Approval announced May 11, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2832,
        "drug_name": "AIMOVIG (Erenumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-17",
        "link": "http:\/\/hugin.info\/134323\/R\/2193680\/849680.pdf",
        "note": "Approval announced May 17, 2018.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2832,
        "drug_name": "AIMOVIG (Erenumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-17",
        "link": "http:\/\/hugin.info\/134323\/R\/2193680\/849680.pdf",
        "note": "Approval announced May 17, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2986,
        "drug_name": "LOKELMA (sodium zirconium cyclosilicate)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Hyperkalaemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-18",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html",
        "note": "Approval announced May 18, 2018.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Fast Track Designation (FTD)",
                "abbreviation": "FTD",
                "description": "Fast Track Designation (FTD)",
                "description_html": "<p>Fast Track Designation (FTD)<\/p>\n"
            }
        ]
    },
    {
        "id": 2449,
        "drug_name": "Prolia (denosumab) ",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Glucocorticoid-induced osteoporosis (GIOP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-21",
        "link": "https:\/\/wwwext.amgen.com\/media\/news-releases\/2018\/05\/fda-approves-prolia-denosumab-for-glucocorticoidinduced-osteoporosis\/",
        "note": "Approval announced May 21, 2018.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3411,
        "drug_name": "PALYNZIQ (Pegvaliase)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Phenylketonuria (PKU)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-24",
        "link": "http:\/\/investors.biomarin.com\/2018-05-24-BioMarin-Receives-Standard-Approval-for-Palynziq-TM-pegvaliase-pqpz-Injection-for-Treatment-of-Adults-with-Phenylketonuria-PKU-a-Rare-Genetic-Disease",
        "note": "Approval announced May 24, 2018.",
        "company_entity_id": 69,
        "company_ticker": "BMRN",
        "company_name": "BioMarin Pharmaceutical Inc.",
        "company_price": "85.1800",
        "company_change": -0.8200000000000001,
        "company_percent_change": -0.95,
        "company_optionable": 1,
        "company_number_of_shares": 188675622,
        "price_change_sparkline": [
            [
                88.08,
                1706677200
            ],
            [
                88.74,
                1706763600
            ],
            [
                88.11,
                1706850000
            ],
            [
                87.72,
                1707109200
            ],
            [
                89.8,
                1707195600
            ],
            [
                89.66,
                1707282000
            ],
            [
                88.15,
                1707368400
            ],
            [
                88.46,
                1707454800
            ],
            [
                88.18,
                1707714000
            ],
            [
                86.13,
                1707800400
            ],
            [
                86.01,
                1707886800
            ],
            [
                88.3,
                1707973200
            ],
            [
                88.77,
                1708059600
            ],
            [
                88.67,
                1708405200
            ],
            [
                88.54,
                1708491600
            ],
            [
                89.97,
                1708578000
            ],
            [
                91.24,
                1708664400
            ],
            [
                90.1,
                1708923600
            ],
            [
                90.68,
                1709010000
            ],
            [
                88.4,
                1709096400
            ],
            [
                86.28,
                1709182800
            ],
            [
                87.14,
                1709269200
            ],
            [
                87.72,
                1709528400
            ],
            [
                86.02,
                1709614800
            ],
            [
                86.77,
                1709701200
            ],
            [
                85.89,
                1709787600
            ],
            [
                85.95,
                1709874000
            ],
            [
                86,
                1710129600
            ],
            [
                85.18,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3319,
        "drug_name": "IMVEXXY (estradiol vaginal inserts)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Moderate-to-severe vaginal pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-30",
        "link": "http:\/\/ir.therapeuticsmd.com\/news-releases\/news-release-details\/therapeuticsmd-announces-fda-approval-tx-004hr-imvexxy-estradiol",
        "note": "CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018.",
        "company_entity_id": 327,
        "company_ticker": "TXMD",
        "company_name": "TherapeuticsMD Inc.",
        "company_price": "2.3850",
        "company_change": 0.16,
        "company_percent_change": 6.95,
        "company_optionable": 1,
        "company_number_of_shares": 10575240,
        "price_change_sparkline": [
            [
                2.26,
                1706677200
            ],
            [
                2.26,
                1706763600
            ],
            [
                2.27,
                1706850000
            ],
            [
                2.29,
                1707109200
            ],
            [
                2.29,
                1707195600
            ],
            [
                2.27,
                1707282000
            ],
            [
                2.29,
                1707368400
            ],
            [
                2.29,
                1707454800
            ],
            [
                2.25,
                1707714000
            ],
            [
                2.24,
                1707800400
            ],
            [
                2.29,
                1707886800
            ],
            [
                2.24,
                1707973200
            ],
            [
                2.26,
                1708059600
            ],
            [
                2.27,
                1708405200
            ],
            [
                2.26,
                1708491600
            ],
            [
                2.26,
                1708578000
            ],
            [
                2.25,
                1708664400
            ],
            [
                2.29,
                1708923600
            ],
            [
                2.35,
                1709010000
            ],
            [
                2.37,
                1709096400
            ],
            [
                2.4,
                1709182800
            ],
            [
                2.54,
                1709269200
            ],
            [
                2.635,
                1709528400
            ],
            [
                2.69,
                1709614800
            ],
            [
                2.45,
                1709701200
            ],
            [
                2.29,
                1709787600
            ],
            [
                2.33,
                1709874000
            ],
            [
                2.23,
                1710129600
            ],
            [
                2.385,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2811,
        "drug_name": "XELJANZ (tofacitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ulcerative colitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-30",
        "link": "https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm609225.htm",
        "note": "Approval announced May 30, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3310,
        "drug_name": "KIT-302",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Osteoarthritis and Hypertension",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-31",
        "link": "https:\/\/www.sec.gov\/Archives\/edgar\/data\/1614744\/000121390018007062\/f6k053118ex99-1_kitov.htm",
        "note": "Approval announced May 31, 2018.",
        "company_entity_id": 867,
        "company_ticker": "PPBT",
        "company_name": "Purple Biotech Ltd.",
        "company_price": "0.7360",
        "company_change": -0.030000000000000027,
        "company_percent_change": -4.1,
        "company_optionable": 1,
        "company_number_of_shares": 25237922,
        "price_change_sparkline": [
            [
                0.66,
                1706677200
            ],
            [
                0.6905,
                1706763600
            ],
            [
                0.73,
                1706850000
            ],
            [
                0.79,
                1707109200
            ],
            [
                0.7619,
                1707195600
            ],
            [
                0.79,
                1707282000
            ],
            [
                0.7999,
                1707368400
            ],
            [
                0.82,
                1707454800
            ],
            [
                0.75,
                1707714000
            ],
            [
                0.7503,
                1707800400
            ],
            [
                0.755101,
                1707886800
            ],
            [
                0.78,
                1707973200
            ],
            [
                0.7595,
                1708059600
            ],
            [
                0.690201,
                1708405200
            ],
            [
                0.7042,
                1708491600
            ],
            [
                0.71,
                1708578000
            ],
            [
                0.695,
                1708664400
            ],
            [
                0.7127,
                1708923600
            ],
            [
                0.6706,
                1709010000
            ],
            [
                0.6995,
                1709096400
            ],
            [
                0.821,
                1709182800
            ],
            [
                0.918,
                1709269200
            ],
            [
                0.83,
                1709528400
            ],
            [
                0.8,
                1709614800
            ],
            [
                0.815,
                1709701200
            ],
            [
                0.8658,
                1709787600
            ],
            [
                0.821,
                1709874000
            ],
            [
                0.768,
                1710129600
            ],
            [
                0.736,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3214,
        "drug_name": "OLUMIANT (baricitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Rheumatoid arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-01",
        "link": "http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=69764&p=irol-newsArticle_print&ID=2352801",
        "note": "FDA approval announced for low dose only - June 1, 2018.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3214,
        "drug_name": "OLUMIANT (baricitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Rheumatoid arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-01",
        "link": "http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=69764&p=irol-newsArticle_print&ID=2352801",
        "note": "FDA approval announced for low dose only - June 1, 2018.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2715,
        "drug_name": "FULPHILA (Neulasta biosimilar)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Neulasta biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-04",
        "link": "http:\/\/investor.mylan.com\/news-releases\/news-release-details\/us-fda-approves-mylan-and-biocons-fulphilatm-pegfilgrastim-jmdb",
        "note": "Approval announced June 4, 2018.",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2386,
        "drug_name": "KEYTRUDA (pembrolizumab) + chemo",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-Line Nonsquamous Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-05",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-expands-lillys-alimtar-pemetrexed-label-include-combination",
        "note": "FDA approval (label expansion) announced June 5, 2018.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2386,
        "drug_name": "KEYTRUDA (pembrolizumab) + chemo",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-Line Nonsquamous Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-05",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-expands-lillys-alimtar-pemetrexed-label-include-combination",
        "note": "FDA approval (label expansion) announced June 5, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4640,
        "drug_name": "RITUXAN (rituximab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pemphigus vulgaris",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-07",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20180607006256\/en\/FDA-Approves-Genentech%E2%80%99s-Rituxan-rituximab-Pemphigus-Vulgaris",
        "note": "Approval announced June 7, 2018.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3018,
        "drug_name": "VENCLEXTA (venetoclax) (MURANO)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-11",
        "link": "https:\/\/www.roche.com\/investors\/updates\/inv-update-2018-06-11.htm",
        "note": "Approval announced June 11, 2018.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3018,
        "drug_name": "VENCLEXTA (venetoclax) (MURANO)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-11",
        "link": "https:\/\/www.roche.com\/investors\/updates\/inv-update-2018-06-11.htm",
        "note": "Approval announced June 11, 2018.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2462,
        "drug_name": "KYPROLIS - (ASPIRE)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-11",
        "link": "http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2354016",
        "note": "sNDA approval announced June 11, 2018.",
        "company_entity_id": 627,
        "company_ticker": "LGND",
        "company_name": "Ligand Pharmaceuticals Incorporated",
        "company_price": "72.3600",
        "company_change": 0.11,
        "company_percent_change": 0.15,
        "company_optionable": 1,
        "company_number_of_shares": 17705287,
        "price_change_sparkline": [
            [
                73.1,
                1706677200
            ],
            [
                74.17,
                1706763600
            ],
            [
                74.54,
                1706850000
            ],
            [
                74.72,
                1707109200
            ],
            [
                75.31,
                1707195600
            ],
            [
                74.51,
                1707282000
            ],
            [
                75.41,
                1707368400
            ],
            [
                75.88,
                1707454800
            ],
            [
                75.64,
                1707714000
            ],
            [
                71,
                1707800400
            ],
            [
                73.62,
                1707886800
            ],
            [
                74.65,
                1707973200
            ],
            [
                73.66,
                1708059600
            ],
            [
                72.37,
                1708405200
            ],
            [
                72.67,
                1708491600
            ],
            [
                73.56,
                1708578000
            ],
            [
                75.87,
                1708664400
            ],
            [
                74.42,
                1708923600
            ],
            [
                89.2,
                1709010000
            ],
            [
                84.35,
                1709096400
            ],
            [
                79.35,
                1709182800
            ],
            [
                78.7,
                1709269200
            ],
            [
                76.28,
                1709528400
            ],
            [
                74,
                1709614800
            ],
            [
                72.71,
                1709701200
            ],
            [
                72.47,
                1709787600
            ],
            [
                73.77,
                1709874000
            ],
            [
                72.25,
                1710129600
            ],
            [
                72.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2462,
        "drug_name": "KYPROLIS - (ASPIRE)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-11",
        "link": "http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2354016",
        "note": "sNDA approval announced June 11, 2018.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4432,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cervical cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-12",
        "link": "http:\/\/investors.merck.com\/news\/press-release-details\/2018\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-Previously-Treated-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer-Whose-Tumors-Express-PD-L1-CPS-Greater-Than-or-Equal-to-1\/default.aspx",
        "note": "Approval announced June 12, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2253,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-13",
        "link": "http:\/\/investors.merck.com\/news\/press-release-details\/2018\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-Treatment-of-Refractory-or-Relapsed-Primary-Mediastinal-Large-B-Cell-Lymphoma-PMBCL\/default.aspx",
        "note": "Approval announced June 13, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4879,
        "drug_name": "AVASTIN (bevacizumab) + chemo",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ovarian cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-13",
        "link": "https:\/\/www.roche.com\/investors\/updates\/inv-update-2018-06-13.htm",
        "note": "FDA approval announced June 13, 2018.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3368,
        "drug_name": "MEKTOVI (\u200bbinimetinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "BRAF mutant melanoma cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-27",
        "link": "http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-biopharma-announces-fda-approval-braftovitm-encorafenib",
        "note": "Approval announced June 27, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4356,
        "drug_name": "QBREXZA (glycopyrronium)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Primary axillary hyperhidrosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-06-29",
        "link": "http:\/\/investor.dermira.com\/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2356602",
        "note": "Approval announced June 29, 2018.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    }
]